Join Growin Stock Community!

Utah medical products, inc.UTMD.US Overview

US StockHealthcare
(No presentation for UTMD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

UTMD AI Insights

UTMD Overall Performance

UTMD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

UTMD Recent Performance

1.48%

Utah medical products, inc.

0.05%

Avg of Sector

-0.31%

S&P500

UTMD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

UTMD Key Information

UTMD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

UTMD Profile

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Price of UTMD

UTMD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

UTMD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.52
PE Ratio (TTM)
19.14
Forward PE
-
PS Ratio (TTM)
5.54
PB Ratio
1.78
Price-to-FCF
19.62
METRIC
VALUE
vs. INDUSTRY
Gross Margin
55.73%
Net Margin
29.30%
Revenue Growth (YoY)
-5.83%
Profit Growth (YoY)
-11.08%
3-Year Revenue Growth
-12.66%
3-Year Profit Growth
-17.18%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.52
PE Ratio (TTM)
19.14
Forward PE
-
PS Ratio (TTM)
5.54
PB Ratio
1.78
Price-to-FCF
19.62
Gross Margin
55.73%
Net Margin
29.30%
Revenue Growth (YoY)
-5.83%
Profit Growth (YoY)
-11.08%
3-Year Revenue Growth
-12.66%
3-Year Profit Growth
-17.18%

  • When is UTMD's latest earnings report released?

    The most recent financial report for Utah medical products, inc. (UTMD) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating UTMD's short-term business performance and financial health. For the latest updates on UTMD's earnings releases, visit this page regularly.

  • Where does UTMD fall in the P/E River chart?

    According to historical valuation range analysis, Utah medical products, inc. (UTMD)'s current price-to-earnings (P/E) ratio is 18.05, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of UTMD?

    According to the latest financial report, Utah medical products, inc. (UTMD) reported an Operating Profit of 2.44M with an Operating Margin of 27% this period, representing a decline of 16.66% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is UTMD's revenue growth?

    In the latest financial report, Utah medical products, inc. (UTMD) announced revenue of 9.04M, with a Year-Over-Year growth rate of -1.24%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does UTMD have?

    At the end of the period, Utah medical products, inc. (UTMD) held Total Cash and Cash Equivalents of 85.76M, accounting for 0.7 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does UTMD go with three margins increasing?

    In the latest report, Utah medical products, inc. (UTMD) achieved the “three margins increasing” benchmark, with a gross margin of 52.31%%, operating margin of 27%%, and net margin of 28.36%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess UTMD's profit trajectory and future growth potential.

  • Is UTMD's EPS continuing to grow?

    According to the past four quarterly reports, Utah medical products, inc. (UTMD)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.77. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of UTMD?

    Utah medical products, inc. (UTMD)'s Free Cash Flow (FCF) for the period is 0, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 100% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of UTMD?

    The latest valuation data shows Utah medical products, inc. (UTMD) has a Price-To-Earnings (PE) ratio of 18.05 and a Price/Earnings-To-Growth (PEG) ratio of -7.13. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.